Aptevo Therapeutics to Present at the 29th Annual ROTH Conference
March 06, 2017 08:30 ET
|
Aptevo Therapeutics
SEATTLE, March 06, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that...
Aptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions
January 13, 2017 09:02 ET
|
Aptevo Therapeutics
SEATTLE, Jan. 13, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it...
Aptevo Therapeutics Presents Data on Its ADAPTIR™ Antibody Platform at the 16th Annual PEPTALK Conference
January 12, 2017 09:02 ET
|
Aptevo Therapeutics
SEATTLE, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that Dr....
Aptevo Therapeutics Resumes IXINITY Manufacturing; Anticipates Re-Entering the Market in the Second Quarter of 2017
January 04, 2017 07:58 ET
|
Aptevo Therapeutics
SEATTLE, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it...
Aptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab
December 16, 2016 09:05 ET
|
Aptevo Therapeutics
SEATTLE, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the...
Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MOR209/ES414
December 15, 2016 13:54 ET
|
Aptevo Therapeutics
SEATTLE, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it...
Aptevo Therapeutics Augments Leadership Team
September 15, 2016 10:30 ET
|
Aptevo Therapeutics
Appoints Former GlaxoSmithKline Executive Randy Maddux Senior Vice President, Operations Jane Gross, Ph.D., Promoted to Senior Vice President and Chief Scientific Officer SEATTLE, Sept. 15,...